https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/728728 Wed, 11 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728728-microbiotica-reports-positive-phase-ib-data-for-live-microbiome-therapeutic Illustration of intestinal track http://www.bioworld.com/articles/712158 Fri, 30 Aug 2024 09:00:00 -0400 https://www.bioworld.com/articles/712158-microbiotica-entering-clinic-with-live-bacterial-therapeutics http://www.bioworld.com/articles/711787 Tue, 27 Aug 2024 00:00:00 -0400 https://www.bioworld.com/articles/711787-microbiotica-entering-clinic-with-live-bacterial-therapeutics Microbiome illustration http://www.bioworld.com/articles/690958 Tue, 25 Oct 2022 12:00:00 -0400 https://www.bioworld.com/articles/690958-gut-microbiota-degrade-intestinal-nicotine-alleviate-smoking-related-liver-disease Illustration of stomach, beneficial gut bacteria. Credit: Darryl Leja, National Human Genome Research Institute, NIH http://www.bioworld.com/articles/690893 Fri, 21 Oct 2022 12:00:00 -0400 https://www.bioworld.com/articles/690893-gut-microbiota-degrade-intestinal-nicotine-alleviate-smoking-related-liver-disease Illustration of stomach, beneficial gut bacteria. Credit: Darryl Leja, National Human Genome Research Institute, NIH Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.]]> http://www.bioworld.com/articles/690695 Wed, 19 Oct 2022 09:00:00 -0400 https://www.bioworld.com/articles/690695-gut-microbiota-degrade-intestinal-nicotine-alleviate-smoking-related-liver-disease http://www.bioworld.com/articles/689801 Tue, 20 Sep 2022 09:00:00 -0400 https://www.bioworld.com/articles/689801-ads-024-restores-movement-in-mice-with-pd Parkinson's disease illustration showing neurons containing alpha-synuclein http://www.bioworld.com/articles/520790 Mon, 18 Jul 2022 12:00:00 -0400 https://www.bioworld.com/articles/520790-nestle-banks-on-enteromes-gut-bacteria-approach-for-ibd-food-allergies http://www.bioworld.com/articles/507222 Tue, 18 May 2021 12:00:00 -0400 https://www.bioworld.com/articles/507222-eurekares-60m-series-a-to-build-support-microbiome-and-synthetic-biology-firms Microbiome illustration Credit: Darryl Leja, NHGRI BioWorld, financing that will help the company launch its phase I trial next year. It has been a year since the drugmaker closed a $14 million series B round. During this period, Tan said Xbiome submitted an IND to the FDA in October for its fecal microbiota transplant (FMT) capsule candidate, a potential treatment for graft-vs.-host disease.]]> http://www.bioworld.com/articles/500800 Tue, 01 Dec 2020 12:00:00 -0500 https://www.bioworld.com/articles/500800-ai-microbiome-firm-xbiome-raises-20m-to-push-candidates-into-clinic Gastrointestinal-microbiome BioWorld.]]> http://www.bioworld.com/articles/498631 Tue, 06 Oct 2020 12:00:00 -0400 https://www.bioworld.com/articles/498631-trekkies-delight-federation-launches-with-a-50m-series-a Clostridioides difficile infection and to move two additional programs, for chronic hepatitis B virus infection and autistic spectrum disorder, into the clinic.]]> http://www.bioworld.com/articles/497903 Thu, 17 Sep 2020 12:00:00 -0400 https://www.bioworld.com/articles/497903-finch-closes-90m-series-d-round-as-microbiome-therapies-start-to-deliver Microbiome illustration http://www.bioworld.com/articles/435930 Tue, 23 Jun 2020 12:00:00 -0400 https://www.bioworld.com/articles/435930-cp-101-hits-primary-endpoint-in-phase-ii-cdi-trial-but-will-finch-take-flight Clostridium difficile bacteria http://www.bioworld.com/articles/434911 Wed, 06 May 2020 12:00:00 -0400 https://www.bioworld.com/articles/434911-rebiotix-reports-positive-phase-iii-efficacy-data-for-its-microbiome-based-therapy BioWorld the potential $1.5 billion-plus agreement involves “biomarkers in multiple disease areas on five of Gilead’s portfolio programs in inflammation, fibrosis and oncology. Associated with that is a drug discovery collaboration around five targets in the context of IBD.”]]> http://www.bioworld.com/articles/434215 Mon, 06 Apr 2020 12:00:00 -0400 https://www.bioworld.com/articles/434215-doubling-down-gilead-counts-on-second-genome-in-potential-15b-pairing Intestine http://www.bioworld.com/articles/433981 Thu, 26 Mar 2020 13:00:00 -0400 https://www.bioworld.com/articles/433981-seventure-leads-think-in-on-microbiome-dealmaking Microbiome illustration http://www.bioworld.com/articles/433912 Tue, 24 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/433912-seventure-leads-think-in-on-microbiome-dealmaking Microbiome illustration http://www.bioworld.com/articles/429447 Wed, 02 Oct 2019 00:00:00 -0400 https://www.bioworld.com/articles/429447-south-koreas-gi-innovation-secures-31m-in-series-b-round-for-microbiome-work http://www.bioworld.com/articles/429362 Fri, 13 Sep 2019 00:00:00 -0400 https://www.bioworld.com/articles/429362-guts-glory-seres-of-tries-in-microbiome-may-yield-success-yet-experts-insist http://www.bioworld.com/articles/429808 Mon, 09 Sep 2019 00:00:00 -0400 https://www.bioworld.com/articles/429808-pku-jujitsu-firms-vying-for-advantage-early-bids-weighed-for-likely-merit